FOLH1 and prostate cancer: Interestingly, in a study, 64 Cu-PSMA-617-PET was demonstrated to be feasible for imaging prostate cancer for both the primary tumor site and metastases, whereas later imaging 2–22 h post-injection showed no additional, clinically relevant benefit compared to the early scans [17].